Want to see TSE:BETR full AI Analyst Report?
BetterLife Pharma (BETR) AI Stock Analysis
BetterLife Pharma
(CNQX:BETR)
The score is primarily constrained by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity indicating elevated financing risk). Technicals add a modest drag with the stock trading below key short/intermediate moving averages and negative MACD, while valuation remains hard to justify given the negative P/E and lack of dividend support.
BetterLife Pharma (BETR) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 111.24M
- Dividend Yield
- ―
- Average Volume (3M)
- 428.55K
- Price to Earnings (P/E)
- -11.4
- Beta (1Y)
- 0.44
- Revenue Growth
- ―
- EPS Growth
- -266.67%
- Country
- Canada
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BetterLife Pharma Business Overview & Revenue Model
Company Description
BetterLife Pharma Inc. is a biotechnology company focused on the global development and commercialization of therapeutic compounds, particularly for neurological disorders. The firm also innovates drug candidates utilizing complementary interferon-ba...
BetterLife Pharma Financial Statement Overview
Summary
Financial quality is weak: no revenue reported, persistent net losses (TTM net loss about $3.5M), and ongoing negative operating/free cash flow (TTM operating cash flow about -$2.1M). While losses and cash burn have improved versus earlier periods, stockholders’ equity remains negative (TTM around -$10.9M), which elevates solvency and funding risk.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | -18.43K | -18.44K |
| EBITDA | -2.56M | -1.81M | 0 | -3.19M | -9.24M | -11.92M |
| Net Income | -3.48M | -1.50M | -3.52M | -2.89M | -9.02M | -12.16M |
Balance Sheet | ||||||
| Total Assets | 2.05M | 219.90K | 224.96K | 324.75K | 74.73K | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 973.59K | 12.57K | 8,180 | 37.38K | 8,307 | 173.51K |
| Total Debt | 2.51M | 905.00K | 1.30M | 1.47M | 1.19M | 1.40M |
| Total Liabilities | 9.70M | 6.71M | 7.59M | 8.02M | 7.61M | 5.04M |
| Stockholders Equity | -10.94M | -9.78M | -10.68M | -10.81M | -10.73M | -3.88M |
Cash Flow | ||||||
| Free Cash Flow | -2.08M | -625.45K | -2.02M | -2.47M | -1.50M | -11.20M |
| Operating Cash Flow | -2.08M | -625.46K | -2.02M | -2.47M | -1.50M | -11.20M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 165.04K | -18.77K |
| Financing Cash Flow | 3.03M | 629.26K | 1.99M | 2.50M | 1.34M | 11.23M |
BetterLife Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Positive. The current price of 0.25 is above the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.29, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.39 is Neutral, neither overbought nor oversold. The STOCH value of 54.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BETR.
BetterLife Pharma Risk Analysis
BetterLife Pharma disclosed 20 risk factors in its most recent earnings report. BetterLife Pharma reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBetterLife Pharma Peers Comparison
Overall Rating
TSE:MDMA50Neutral
TSE:PHRM48Neutral
TSE:MRVL46Neutral- TSE:BETR43Neutral
TSE:CSCI42Neutral
TSE:MOOD42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:MDMA | 50Neutral | CAD 18.57M | -11.41 | -72.15% | ― | 224.46% | 28.37% |
| TSE:PHRM | 48Neutral | CAD 5.01M | -13.10 | -75.59% | ― | ― | 75.84% |
| TSE:MRVL | 46Neutral | CAD 7.56M | -4.49 | 39.05% | ― | ― | 25.70% |
| TSE:BETR | 43Neutral | CAD 154.50M | -11.36 | 34.90% | ― | ― | -266.67% |
| TSE:CSCI | 42Neutral | CAD 8.37M | -0.46 | -48.52% | ― | -13.00% | 75.31% |
| TSE:MOOD | 42Neutral | CAD 680.99K | -0.57 | -85.01% | ― | 73.76% | -108.30% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:BETR | Betterlife Pharma Inc. | 0.25 | 0.19 | 316.67% | |
| TSE:CSCI | Cosciens Biopharma Inc. | 8.40 | -2.31 | -21.57% | |
| TSE:PHRM | PharmaTher Holdings Ltd | 0.06 | -0.06 | -50.00% | |
| TSE:MRVL | Marvel Biosciences Corp | 0.12 | -0.10 | -45.45% | |
| TSE:MOOD | Doseology Sciences, Inc. | 0.09 | -0.26 | -75.71% | |
| TSE:MDMA | PharmAla Biotech Holdings, Inc. | 0.17 | 0.05 | 41.67% |
BetterLife Pharma Corporate Events
BetterLife Pharma Taps LifeSci Advisors as It Advances BETR-001 Toward 2027 Clinical Milestones
PositiveBetterLife Pharma has appointed LifeSci Advisors as its investor relations and corporate communications firm as it prepares BETR-001 for key development milestones. The engagement aims to expand investor outreach through digital marketing, media prog...
BetterLife Pharma Strengthens Headache Program with New Scientific Advisory Co-Chair
PositiveBetterLife Pharma has appointed Professor Richard B. Lipton, a leading neurologist and Director of the Montefiore Headache Center, as Co-Chair of its Scientific Advisory Board for BETR-001. Lipton, a past President of the American Headache Society an...
BetterLife Pharma Taps Clinical Veteran to Lead BETR-001 First-in-Human Study
PositiveBetterLife Pharma has appointed clinical development veteran Sheila Leitzinger as Head of Clinical Operations to oversee trial planning and execution for its first-in-human healthy volunteer study of BETR-001. Her nearly three decades of experience i...
BetterLife Pharma Taps Migraine Pioneer to Lead BETR-001 Headache Program
PositiveBetterLife Pharma has formed a Scientific Advisory Board to steer the clinical development of its lead candidate BETR-001 in chronic cluster headache and chronic migraine, appointing renowned neurologist and Brain Prize co-recipient Professor Peter G...
BetterLife Pharma Faces Legal Dispute With Director Over Convertible Debenture
NegativeBetterLife Pharma has disclosed that independent director Steven Sangha has filed a Notice of Civil Claim in the Supreme Court of British Columbia over the treatment of a convertible debenture issued to him in June 2026. The dispute centers on Sangha...
BetterLife Pharma Resets Shareholder Meeting to Advance Nasdaq Listing Plans
PositiveBetterLife Pharma has rescheduled its 2026 Annual General Meeting and reclassified it as an Annual General and Special Meeting to accommodate additional matters requiring shareholder approval. The virtual meeting will now be held on December 9, 2026,...
BetterLife Pharma Raises US$100 Million to Advance Neurological Drug BETR-001
PositiveBetterLife Pharma has closed a public offering of common shares and pre-funded warrants, raising approximately US$100 million to support the development of its BETR-001 program. The financing, led by Deep Track Capital alongside other specialist heal...
BetterLife Pharma Taps Veteran Biotech Strategist Charles Duncan to Lead Audit Committee
PositiveBetterLife Pharma has appointed Charles Duncan, PhD, a veteran biotechnology strategist and former top-ranked Wall Street biotech analyst, as Director and Chair of its Audit Committee. Duncan brings nearly three decades of experience spanning corpora...
BetterLife Pharma Prices US$100 Million Equity Offering to Advance Neurology Trials
PositiveBetterLife Pharma has priced a public offering of up to 555 million common shares and pre-funded warrants at C$0.25 per share, targeting gross proceeds of US$100 million. The securities will be sold on a commercially reasonable efforts basis through...
BetterLife Pharma Plans Equity Offering to Advance Neurological Trial Program
PositiveBetterLife Pharma Inc., a Vancouver-based biotechnology company, is focused on developing BETR-001, a non-hallucinogenic LSD derivative for neurological disorders, supported by patents covering synthesis and pending protection for composition and use...
BetterLife Pharma Names Veteran Migraine Specialist as CMO to Drive BETR-001 Development
PositiveBetterLife Pharma has appointed neurologist and headache specialist Dr. Mahan Chehrenama as Chief Medical Officer to lead clinical development of its lead asset, BETR-001, a non-hallucinogenic neuroplastogen being advanced toward an IND application f...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026